ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


SEARCH JOBS








 Company News
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Improves OutcomesFor Pancreatic Ductal Adenocarcinoma In Mouse Models 4/20/2015 12:06:33 PM
Pharmacyclics (PCYC) Release: IMBRUVICA (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, In Patients With Chronic Lymphocytic Leukemia (CLL) 4/20/2015 11:34:21 AM
AbbVie (ABBV) Extends Exchange Offer To Acquire Pharmacyclics (PCYC) 4/20/2015 9:28:49 AM
Pharmacyclics (PCYC) Release: New Longer-Term IMBRUVICA (ibrutinib) Data Show High Response Rates In Patients With Waldenstrom's Macroglobulinemia 4/9/2015 7:52:40 AM
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015 8:31:26 AM
Pharmacyclics (PCYC) Release: New ibrutinib (IMBRUVICA) Data To Be Presented At American Association for Cancer Research Meeting 3/19/2015 10:17:29 AM
Pharmacyclics (PCYC) Release: Independent Data Monitoring Committee Unanimously Recommends Unblinding Of IMBRUVICA (Ibrutinib) Phase III Combination HELIOS Trial Based On Interim Analysis Showing Significant Improvement In Progression-Free Survival In Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma 3/17/2015 5:57:01 AM
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial 3/17/2015 5:56:00 AM
Inside The $21 Billion Bidding War For Pharmacyclics (PCYC) 3/6/2015 6:52:51 AM
AbbVie (ABBV) Overpaid in Pharmacyclics (PCYC) Deal, For Only 50% Rights to Imbruvica: Analyst 3/5/2015 12:45:43 PM
12345678910...